Role of the Histone Deacetylase Inhibitor Givinostat (ITF2357) in Treatment of CRLF2 Rearranged Acute Lymphoblastic Leukemia

被引：0

作者：

Savino, Angela Maria ^{[1
]}

Sarno, Jolanda ^{[1
]}

Trentin, Luca ^{[2
]}

Vieri, Margherita ^{[1
]}

Fazio, Grazia ^{[1
]}

Bardini, Michela ^{[1
]}

Bugarin, Cristina ^{[1
]}

Fossati, Gianluca ^{[3
]}

Davis, Kara L. ^{[4
]}

Gaipa, Giuseppe

Meyer, Lueder Hinrich ^{[5
]}

Nolan, Garry P. ^{[6
]}

Biondi, Andrea ^{[7
]}

Kronnie, Geertruy Te ^{[8
]}

Palmi, Chiara ^{[1
]}

Cazzaniga, Giovanni ^{[1
]}

机构：

[1] Univ Milano Bicocca, Dept Pediat, Ctr Ric Tettamanti, Fdn MBBM,San Gerardo Hosp, Monza, Italy

[2] Univ Padua, Dept Womens & Childrens Hlth 2, Padua, Italy

[3] Italfarmaco SpA, Preclin R&D Dept 3, Milan, Italy

[4] Stanford Univ, Pediat, Palo Alto, CA 94304 USA

[5] Univ Ulm, Med Ctr, Dept Pediat & Adolescent Med, D-89069 Ulm, Germany

[6] Stanford Univ, Sch Med, Baxter Lab Stem Cell Biol, Dept Microbiol & Immunol, Palo Alto, CA 94304 USA

[7] Univ Milano Bicocca, Clin Pediat, Ctr Ric Tettamanti, Osped San Gerardo,Fdn MBBM, Monza, MB, Italy

[8] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] ITF2357, a histone deacetylase inhibitor protects barrier function in polarized ARPE-19 cells
Chaurasia, Shyam S.
Lim, Rayne
Mehta, Milan
Tan, Alison
Ghosh, Arkasubhra
Hunziker, Walter
Barathi, Veluchamy A.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
[22] Decreased whole blood cytokine production during a phase I trial of the histone deacetylase inhibitor ITF2357
Oldoni, Tiziano
Furlan, Antonio
Monzani, M. Valmen
Dinarello, Charles A.
CYTOKINE, 2009, 48 (1-2) : 120 - 120
[23] Histone deacetylase inhibitor ITF2357 is effective on the P39 cells. A gene expression study
Petrini, M.
Galimberti, S.
Canestraro, M.
Savli, H.
Palumbo, G. A.
Nagy, B.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[24] The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
Guerini, V.
Barbui, V.
Spinelli, O.
Salvi, A.
Dellacasa, C.
Carobbio, A.
Introna, M.
Barbui, T.
Golay, J.
Rambaldi, A.
LEUKEMIA, 2008, 22 (04) : 740 - 747
[25] The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
V Guerini
V Barbui
O Spinelli
A Salvi
C Dellacasa
A Carobbio
M Introna
T Barbui
J Golay
A Rambaldi
Leukemia, 2008, 22 : 740 - 747
[26] Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma
Marta Di Martile
Marianna Desideri
Maria Grazia Tupone
Simonetta Buglioni
Barbara Antoniani
Carlotta Mastroiorio
Rita Falcioni
Virginia Ferraresi
Nicola Baldini
Roberto Biagini
Michele Milella
Daniela Trisciuoglio
Donatella Del Bufalo
Oncogenesis, 7
[27] Histone deacetylase inhibitor ITF2357 induces apoptosis and increases doxorubicin cytotoxicity in preclinical models of human sarcoma
Tupone, Maria Grazia
Di Martile, Marta
Desideri, Marianna
Buglioni, Simonetta
Antoniani, Barbara
Mastroiorio, Carlotta
Falcioni, Rita
Ferraresi, Virginia
Baldini, Nicola
Biagini, Roberto
Milella, Michele
Trisciuoglio, Daniela
Del Bufalo, Donatella
CANCER RESEARCH, 2018, 78 (13)
[28] Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma
Di Martile, Marta
Desideri, Marianna
Tupone, Maria Grazia
Buglioni, Simonetta
Antoniani, Barbara
Mastroiorio, Carlotta
Falcioni, Rita
Ferraresi, Virginia
Baldini, Nicola
Biagini, Roberto
Milella, Michele
Trisciuoglio, Daniela
Del Bufalo, Donatella
ONCOGENESIS, 2018, 7
[29] Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma (vol 145, pg 393, 2019)
Marampon, Francesco
Leoni, Flavio
Mancini, Andrea
Pietrantoni, Ilaria
Codenotti, Silvia
Ferella, Letizia
Megiorni, Francesca
Porro, Giuliana
Galbiati, Elisabetta
Pozzi, Pietro
Mascagni, Paolo
Budillon, Alfredo
Maggio, Roberto
Tombolini, Vincenzo
Fanzani, Alessandro
Gravina, Giovanni Luca
Festuccia, Claudio
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (09) : 2411 - 2411
[30] Poor Outcome of CRLF2 Rearranged Philadelphia Negative Acute Lymphoblastic Leukemia Adults Patients
Elnahass, Yasser H.
Fahmy, Omar A.
Samra, Mohamed Abdel Mooti
Elrefaey, Fatma A.
Bokhary, Mahmoud T.
Elsherif, Haitham
Afifi, Hazem H.
Elkomy, Abdallah S.
Hola, Mona
Mahmoud, Hossam K.
BLOOD, 2018, 132

← 1 2 3 4 5 →